SCHEMBL30897992

SCHEMBL30897992

CC(C)(C)OC(=O)N1CCC(=CF)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
GRM5 P41594 1/20 0.47
ESR2 Q92731 1/20 0.44
ADORA1 P30542 1/20 0.44
NR1H2 P55055 1/20 0.43
HPGD P15428 1/20 0.43
GPR119 Q8TDV5 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
RECQL P46063 1/20 0.41
EPHX1 P07099 1/20 0.41
MAPT P10636 2/20 0.40
KDM4E B2RXH2 1/20 0.40
THRB P10828 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
PTPN2 P17706 1/20 0.40
PTPN1 P18031 1/20 0.40
PTPN6 P29350 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30857796 0.90 ESR2 (0.49) USP2SMN1; SMN2GRM5ESR2ADORA1
SCHEMBL30857785 0.90 ESR2 (0.49) USP2SMN1; SMN2GRM5ESR2ADORA1
SCHEMBL24673913 0.84 USP2 (0.51) USP2SMN1; SMN2GRM5ESR2ADORA1
SCHEMBL10253506 0.84 USP2 (0.51) USP2SMN1; SMN2GRM5ESR2ADORA1
SCHEMBL18711868 0.83 GRM5 (0.48) USP2SMN1; SMN2GRM5ESR2ADORA1
SCHEMBL513246 0.83 USP2 (0.50) USP2SMN1; SMN2GRM5ESR2ADORA1
SCHEMBL1689676 0.81 USP2 (0.49) USP2SMN1; SMN2GRM5ESR2ADORA1
SCHEMBL3719620 0.81 USP2 (0.49) USP2SMN1; SMN2GRM5ESR2ADORA1
SCHEMBL2948300 0.81 USP2 (0.49) USP2SMN1; SMN2GRM5ESR2ADORA1
SCHEMBL843458 0.81 USP2 (0.49) USP2SMN1; SMN2GRM5ESR2ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122029167-A Condensed heteroaryl compound, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2026-05-12 CN disclosed
CN-119684315-B Crystal form of benzothiophene substituted fused ring compound and preparation method thereof 苏州盛迪亚生物医药有限公司 2026-05-12 CN disclosed
EP-4735451-A1 SUBSTITUTED CONDENSED TRICYCLIC AMINE COMPOUNDS AND USES THEREOF AS RAS INHIBITORS Kumquat Biosciences Inc. (US) 2026-05-06 EP disclosed
EP-4635958-A1 PYRIMIDINE-CONTAINING POLYCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2025-10-22 EP disclosed
EP-4563580-A1 FUSED RING COMPOUND, PREPARATION METHOD THEREFOR AND MEDICINAL APPLICATION THEREOF Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) 2025-06-04 EP disclosed
WO-2025092798-A1 FUSED HETEROARYL COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE 江苏恒瑞医药股份有限公司 2025-05-08 WO disclosed
CN-119684316-A Crystal form of benzothiophene substituted fused ring compound and preparation method thereof 苏州盛迪亚生物医药有限公司 2025-03-25 CN disclosed
CN-119661556-A Pharmaceutically acceptable salts of condensed ring compounds, crystalline forms and uses thereof 苏州盛迪亚生物医药有限公司 2025-03-21 CN disclosed
CN-119661555-A Pharmaceutically acceptable salts of condensed ring compounds, crystalline forms and uses thereof 苏州盛迪亚生物医药有限公司 2025-03-21 CN disclosed
WO-2025059040-A1 MUTANT KRAS MODULATORS AND USES THEREOF NEWAVE PHARMACEUTICAL INC. (US) 2025-03-20 WO disclosed
CN-119613432-A Pharmaceutically acceptable salt of benzothiophene substituted fused ring compound, crystal form and application thereof 苏州盛迪亚生物医药有限公司 2025-03-14 CN disclosed
CN-119490512-A Pharmaceutically acceptable salt of benzothiophene substituted fused ring compound, crystal form and application thereof 苏州盛迪亚生物医药有限公司 2025-02-21 CN disclosed
CN-119365465-A Condensed ring compound, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2025-01-24 CN disclosed
WO-2025007000-A1 SUBSTITUTED CONDENSED TRICYCLIC AMINE COMPOUNDS AND USES THEREOF AS RAS INHIBITORS KUMQUAT BIOSCIENCES INC. (US) 2025-01-02 WO disclosed
WO-2024104453-A1 FUSED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF 江苏恒瑞医药股份有限公司 2024-05-23 WO disclosed